April 26, 2023 03:48 PM EDT

Following CRL, Form 483 reveals more quality issues at Alvotech’s production facility in Iceland

Tyler Patchen

News Reporter

Another Form 483 for the Icelandic biosimilar manufacturer Alvotech’s manufacturing facility has shed more light on a recent complete response letter from the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Following CRL, Form 483 reveals more quality issues at Alvotech’s production facility in Iceland

Tyler Patchen

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

China’s biotech market is staging a comeback that US biotech can only wish for

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

Genentech vet launches ADC startup with $20M

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Fol­low­ing CRL, Form 483 re­veals more qual­i­ty is­sues at Alvotech’s pro­duc­tion fa­cil­i­ty in Ice­land

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Following CRL, Form 483 reveals more quality issues at Alvotech’s production facility in Iceland